<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4926">
  <stage>Registered</stage>
  <submitdate>6/03/2015</submitdate>
  <approvaldate>6/03/2015</approvaldate>
  <nctid>NCT02386098</nctid>
  <trial_identification>
    <studytitle>Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults</studytitle>
    <scientifictitle>A Phase 2b Randomized, Active-Controlled, Staged, Open-label Trial to Investigate Safety and Efficacy of BMS-955176 in Combination With Dolutegravir and Atazanavir (With or Without Ritonavir) in Treatment-Experienced HIV-1 Infected Adults</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AI468-048</secondaryid>
    <secondaryid>205892</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infection, Human Immunodeficiency Virus</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-955176
Treatment: drugs - Atazanavir (ATV)
Treatment: drugs - Ritonavir (RTV)
Treatment: drugs - Dolutegravir (DTG)
Treatment: drugs - Tenofovir (TDF)

Experimental: Arm 1: BMS-955176 + ATV + RTV + DTG - BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally

Other: Arm 2: TDF + ATV + RTV + DTG - TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally

Experimental: Arm 3: BMS-955176 + ATV + DTG - BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally

Experimental: Arm 4: BMS-955176 + ATV + DTG - BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally

Other: Arm 5: TDF + ATV + RTV + DTG - TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally


Treatment: drugs: BMS-955176
HIV Maturation Inhibitor

Treatment: drugs: Atazanavir (ATV)
Atazanavir

Treatment: drugs: Ritonavir (RTV)
Ritonavir

Treatment: drugs: Dolutegravir (DTG)
Dolutegravir

Treatment: drugs: Tenofovir (TDF)
Tenofovir

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The proportion of subjects with plasma HIV 1 RNA less than 40 c/mL at Week 24</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The antiviral efficacy of BMS-955176 Arms, and the TDF-containing Arms (TDF + ATV/r + DTG), by determining the proportion of treatment-experienced subjects with plasma HIV-1 RNA less than 40 c/mL</outcome>
      <timepoint>At Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The antiviral efficacy of BMS-955176 Arms, and the TDF-containing Arms, by determining the proportion of treatment-experienced subjects with plasma HIV-1 RNA less than 200 c/mL</outcome>
      <timepoint>At Weeks 24,48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The emergence of HIV drug resistance in samples selected for drug resistance testing</outcome>
      <timepoint>At Weeks 24,48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy of BMS-955176 Arms, and the TDF-containing Arms, by using the mean changes from baseline in log10 HIV-1 RNA, CD4+ T-cell counts, and percentage of CD4+ T cells</outcome>
      <timepoint>At Weeks 24,48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability of BMS-955176 in treatment-experienced subjects by measuring frequency of serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation</outcome>
      <timepoint>At Weeks 24,48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease progression as measured by the occurrence of new Acquired immune deficiency syndrome (AIDS) defining events (CDC Class C events)</outcome>
      <timepoint>At Weeks 24,48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve (AUC) of BMS-955176</outcome>
      <timepoint>At Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed concentration (Cmax) of BMS-955176</outcome>
      <timepoint>At Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men and non-pregnant women, at least 18 years of age

          -  Antiretroviral treatment-experienced, defined as having documented evidence of having
             failed 1 or 2 regimens that include 2 or 3 classes of antiretroviral (ARV) (with or
             without documented resistance)

          -  CD4+ T-cell count &gt; 50 cells/mm3

          -  Screening genotype/phenotype indicating susceptibility to study drugs (unboosted ATV,
             FC &lt; 2.2; DTG; TDF)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Antiretroviral treatment-experienced adults who have failed &gt; 2 ARV regimens

          -  Resistance or partial resistance to any study drug determined by tests at Screening

          -  Historical or documented genotypic and/or phenotypic drug resistance testing showing
             certain resistance mutations to ATV, TDF, RAL, Protease Inhibitors, and certain TAMs

          -  Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV)

          -  Blood tests that indicate normal liver function

          -  Hemoglobin &lt; 8.0 g/dL, Platelets &lt; 50,000 cells/mm3</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>8/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>84</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>7/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>GSK Investigational Site - Darlinghurst, Sydney</hospital>
    <hospital>GSK Investigational Site - Darlinghurst</hospital>
    <hospital>GSK Investigational Site - Sydney</hospital>
    <postcode>2010 - Darlinghurst, Sydney</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2010 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Santa Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Córdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mar del Plata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Región Metro De Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Providencia, Santiago de Chile</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Barranquilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogotá</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Chihuahua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>DF</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Oaxaca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ekaterinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Irkutsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Krasnodar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Eastern Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Free State</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Tembisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Westdene</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ViiV Healthcare</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>GlaxoSmithKline</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate whether the combination of BMS-955176 with
      atazanavir (ATV) [with or without ritonavir (RTV)] and dolutegravir (DTG) is efficacious,
      safe, and well-tolerated in HIV-1 infected treatment experienced adults.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02386098</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>ViiV Healthcare</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>